All In MedTech

Device Trial Radar · NCT02556255

Safety and Effectiveness Study of Eximo's B-Laser™ Atherectomy Device for PAD Treatment

Safety and Effectiveness Evaluation of Eximo's B-Laser™ Atherectomy Device, in Subjects Affected With PAD

Last checked: Nov 20, 2026Latest source record: Mar 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Oct 2015

Primary completion

Aug 2017

Study completion Nov 20, 2020

Sponsor

Lead sponsor
Eximo Medical Ltd.Not on our public-company list
Sponsor type
Industry
Collaborators
KCRI
First posted
Sep 22, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the safety and efficacy of the use of the Eximo's B-Laser™ catheter in subjects affected with Peripheral Artery Disease (PAD) in lower extremity arteries.

Conditions

  • Peripheral Arterial Disease

Interventions

  • B-Laser™ Atherectomy CatheterDevice

    Laser atherectomy catheter based on 355 nm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With 30 Day Freedom From Major Adverse EventsTime frame: 30 days post procedure

2 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach

    Katowice, Poland

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.